Phase 1 Obesity Trial, Recruiting (NCT07142707)

Phase 1 Obesity Trial, Recruiting NCT07142707 Sponsor: MBX Biosciences Condition: Obesity

Printed from Voxsanity (voxsanity.com.au) — NCT07142707 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Obesity

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are older than 18 and up to 65 years of age at the time of signing the consent forms.
People with a BMI between 30 and just under 50 kg/m² at the screening and baseline appointments.
People whose weight has been stable for at least 3 months before screening, meaning their weight has not changed by more than 5% in either direction during that time or between screening and baseline.

Who may not be able to join:

People with a significant illness or medical condition that the trial doctor believes could prevent safe participation in the study.
People who have had, or currently have, pancreatitis, type 1 diabetes, or type 2 diabetes.
People whose obesity is caused by a specific underlying medical condition, such as a hormonal disorder, a genetic condition, or a brain-related cause (confirm with trial site).
People who have a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma, or a condition called multiple endocrine neoplasia syndrome type 2.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 844-877-4473

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07142707

Sponsor: MBX Biosciences

Phase: Phase 1

Status: Recruiting

Condition: Obesity

Trial contact: 844-877-4473

More information: https://clinicaltrials.gov/study/NCT07142707

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are older than 18 and up to 65 years of age at the time of signing the consent forms.
People with a BMI between 30 and just under 50 kg/m² at the screening and baseline appointments.
People whose weight has been stable for at least 3 months before screening, meaning their weight has not changed by more than 5% in either direction during that time or between screening and baseline.

Who may not be able to join:

People with a significant illness or medical condition that the trial doctor believes could prevent safe participation in the study.
People who have had, or currently have, pancreatitis, type 1 diabetes, or type 2 diabetes.
People whose obesity is caused by a specific underlying medical condition, such as a hormonal disorder, a genetic condition, or a brain-related cause (confirm with trial site).
People who have a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma, or a condition called multiple endocrine neoplasia syndrome type 2.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

MBX Biosciences

Registry

ClinicalTrials.gov

Start date

3 September 2025

Est. completion

30 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with Treatment Emergent Adverse Events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov